Axl and the estrogen receptor (ER) have high expression correlation in a subset of breast cancer, and treatment of ER+ cells with an ER antagonist or depriving them of estrogen decreases Axl expression [109, 118]. This evidence concerns the gene ESR1 and breast carcinoma.